John Oyler Sells 3,410 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,410 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80. Following the completion of the sale, the chief executive officer directly owned 1,610 shares in the company, valued at approximately $440,785.80. This represents a 67.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 1.7%

BeOne Medicines stock opened at $279.89 on Friday. The firm has a 50-day moving average of $291.75 and a 200-day moving average of $310.21. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market cap of $30.71 billion, a price-to-earnings ratio of 62.62 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion for the quarter. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently made changes to their positions in ONC. EFG International AG bought a new stake in BeOne Medicines in the 4th quarter valued at $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the second quarter worth $35,000. CWM LLC boosted its position in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new position in shares of BeOne Medicines in the fourth quarter valued at about $61,000. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ONC shares. Leerink Partners increased their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Wolfe Research started coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Wall Street Zen cut shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 20th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.